ArticleCells2026
Behaviour of iPSC-Derived and Donor-Derived Hepatic Stellate Cells in Organoid Cultures Is Highly Variable and Contributes to Fibrotic Outcome.
Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hepatic stellate cells (HSCs) are central drivers of liver fibrosis, yet their heterogeneity is often overlooked in human liver organoid models. Here, we investigated how HSC-intrinsic variability influences fibrotic phenotypes in multicellular liver organoids using induced pluripotent stem cell-derived HSCs (iHSCs) and primary HSCs (pHSCs). iHSCs derived from two different iPSC lines exhibited distinct differentiation phenotypes towards iHSCs. Consistently, co-culture of the hepatocyte-like cell line HepaRG with these two iHSC populations generated organoids with distinct fibrotic and hepatic features. BJ1-iHSC/HepaRG organoids contained an approximately 2.9-fold higher proportion of CYP3A4-positive cells, whereas Sigma-iHSC/HepaRG organoids showed around a 4-fold higher percentage of Sirius red-positive area. Single-cell RNA analysis further showed that the two iHSC populations differed in cell cycle distribution, HSC-related signatures, extracellular matrix-associated pathways, and matrisome enrichment. Similarly, human pHSCs cultured as organoids with HepaRG showed marked donor-dependent differences at baseline and after single acetaminophen, repeated thioacetamide or transforming growth factor beta treatment. Together, our findings suggest that HSC heterogeneity, whether iPSC-derived or donor-derived, is an important factor in fibrotic output and response variability in human liver organoid models and should be considered in model design, interpretation and comparison between studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.